

CURRICULUM VITAE

Andrew James Phillips
MBCChB BSc MA MRCOG DFRSH PGCME

May 2026

PERSONAL DETAILS

Name: Andrew James Phillips

Location: Derby

Telephone: 07888735584

Email: andy@phillips-richardson.co.uk

Professional Memberships:

- General Medical Council:
 - 01.11.14 Obstetrics and Gynaecology
 - 5.10.17 Gynaecological Oncology
- Royal College of Obstetricians and Gynaecologists
- British Gynaecological Cancer Society
- British Society for Colposcopy and Cervical Pathology
- European Society of Gynaecological Oncology
- International Gynaecological Cancer Society

QUALIFICATIONS

DEGREES

Date	Qualification	Awarding Body
2009	MA Health Ethics & Law	University of Manchester
2005	MChB	University of Bristol
2004	BSc Bioethics	University of Bristol

DIPLOMAS

Date	Qualification	Awarding Body
2011	Family Planning, Sexual & Reproductive Health	FSRH/RCOG

CERTIFICATES

Date	Qualification	Awarding Body
2013	Medical Education	University of Dundee

PROFESSIONAL QUALIFICATIONS

Date	Qualification	Awarding Body
2018	Colposcopist & Trainer	BSCCP
2016	Colposcopy (Diagnosis and Treatment)	BSCCP
2011	MRCOG	RCOG
2010	MRCP parts 1 and 2	RCP

ADVANCED TRAINING SKILLS MODULES & SUB SPECIALITY TRAINING

Date	Qualification	Awarding Body
2017	Gynaecological Oncology SST	RCOG
2014	Oncology	RCOG
2014	Advanced Labour Ward Practice	RCOG

POSITIONS OF RESPONSIBILITY NHS

Date	Role	Location
2021 →	Lead Cancer clinician (UHDB)	Local
2017 →	Lead for Gynaecological Family History	Local

2018-2024	Lead for Gynaecological Cancer	Local
2018-2019	Lead for 100,000 genomes project	Local
2010-2011	Junior Doctor BMA Representative	Local
2008-2009	Junior Representative Local Negotiation Committee	Local

POSITIONS OF RESPONSIBILITY EXTERNAL

Date	Role	Location
2025 →	Secretary BGCS	National
2023 →	BGCS Representative: National Ovarian Cancer Audit (NOCA)	National
2022-2025	Treasurer BGCS	National
2021-2024	Surgical Project Lead: IMPROVE UK	National
2021-2023	Member: Progressing Gynaecology Cancer Collaborative	Regional
2021-2022	Lead: Surgical Subgroup for ECAG	Regional
2020-2021	Member: BGCS Ovarian Cancer Call to action Panel	National
2021-2022	BGCS representative on BAGP panel for specialist pathology review	National
2020-2022	Midlands Representative – BGCS	National
2018-2021	BGCS Advisory Group - Ovarian Cancer Feasibility Pilot	National

RELATING TO MEDICOLEGAL PRACTICE:

No.	Qualification	Awarding Body	Year
3	Bond Solon: Civil Law and Procedure for Expert Witnesses	Bond Solon	2026
2	Bond Solon: Report Writing for Expert Witnesses	Bond Solon	2026
1	Bond Solon: Courtroom Skills	Bond Solon	2026

PERSONAL STATEMENT

I am a Consultant Gynaecological Oncologist with subspecialist accreditation in Obstetrics and Gynaecology and over a decade of senior clinical experience in complex cancer surgery and multidisciplinary care. My practice encompasses the diagnosis and management of cervical, endometrial, ovarian and vulval malignancies, advanced cytoreductive surgery, hereditary cancer risk management, and the governance of cancer pathways within a large UK teaching hospital.

From the outset of my medical career, I have maintained a strong academic and professional interest in ethics, law and patient communication. I completed an intercalated BSc in Bioethics followed by a Master's degree in Health Ethics and Law, which has provided a structured framework for analysing consent, capacity, professional standards, duty of care and complex decision-making. This academic foundation underpins my medico-legal work and informs my approach to balanced, evidence-based expert opinion. I have completed Bond Solon courses on Report Writing for Expert Witnesses, Court Room skills & Civil Law and Procedure for Expert Witnesses.

I have served as Lead Clinician for Gynaecological Cancer and currently hold the role of Lead Cancer Clinician within my Trust. These leadership positions have required detailed scrutiny of clinical pathways, guideline compliance, audit data, morbidity and mortality review, and quality assurance processes. I have led the development and revision of tumour-specific operational policies, consent documentation, and patient information materials, and have overseen service redesign to meet national and European quality standards. Under my leadership, our unit achieved European certification for advanced ovarian cancer surgery and has demonstrated high regional survival outcomes.

I am actively involved in national governance and guideline development through the British Gynaecological Cancer Society, contributing to national guidance and audit programmes. My publication record includes peer-reviewed research in surgical outcomes, performance indicators, benchmarking methodology and standards of care in gynaecological oncology. I regularly review manuscripts for leading journals and contribute to the appraisal of clinical evidence at a national level. This work ensures my opinions are grounded in current literature, national guidance and contemporary practice.

My clinical practice includes high-complexity surgery, peri-operative risk assessment, multidisciplinary treatment planning, and the management of complications. I am experienced in analysing documentation, evaluating adherence to standards, and assessing causation in complex oncological pathways. I understand the importance of clarity, objectivity and independence in medico-legal reporting and am committed to producing structured, balanced and defensible expert reports for the Court.

I am able to provide expert opinion in cases relating to:

- Delay in diagnosis of gynaecological malignancy
- Surgical management of ovarian, cervical and endometrial cancer
- Consent and risk disclosure in major gynaecological surgery
- Post-operative complications and peri-operative decision-making
- Follow-up protocols and cancer surveillance
- Hereditary cancer risk management and family history services
- Multidisciplinary cancer pathway governance

My approach is methodical, impartial and evidence-based. I recognise the responsibility placed upon expert witnesses and the necessity to remain independent of instructing parties. My aim is always to assist the Court through clear analysis of the facts against accepted standards of practice at the relevant time.

EMPLOYMENT HISTORY

From	Grade	Hospital	Specialty	Supervisor
Aug 2017	Consultant	Royal Derby	Gynae-Oncology	
April 2014	SST	Birmingham City	Gynae-Oncology	Miss K Singh
Aug 2013	ST7	Royal Derby	Gynae-Oncology Vulval Disease	Mr J Balega Mr S Abdul Mr A Bali Mr V Asher
Oct 2012	ST6	Royal Derby	Gynae-Oncology Vulval Disease	Mr S Abdul Mr A Bali Mr V Asher
Oct 2011	ST5	Royal Cornwall	Gynae-Oncology Maternal Medicine	Mr T Lopes Mr N Das Miss K Watkins
Oct 2010	ST4	Royal Cornwall	Gynae-Oncology Minimal Access Surgery Fetal Medicine/Urogynae	Mr T Lopes Mr N Das Mr R Holmes
Aug 2009	ST3	Royal Devon and Exeter	Gynae-Oncology Fetal/Maternal Medicine	Mr J Rennison Mr M Taylor Mr B Peyton-Jones
Aug 2008	ST2	Royal Devon and Exeter	Gynae-Oncology Subfertility	Mr N Acheson Mr J Rennison Mr J West
Aug 2007	ST1	Torbay District General	Gynae-Oncology Minimal Access Surgery	Mr P Stannard Miss M Leggott Mr J Hindley
Aug 2006	FY2	Torbay District General	O&G GPA&E	Miss M Leggott Dr N Cooper Mr C Manlow
Aug 2005	FY1	Cheltenham General	GP MAU Gastroenterology Vascular Surgery	Dr R Estelrich Dr I Mortimore Dr I Crossley Mr K Poskitt

RESEARCH

STUDY INVOLVEMENT

RESEACH/NATIONAL AUDIT INVOLVEMENT

No.	Study	Type	Role	Year
13	PROTECTOR2	STUDY	PI (Derby)	2026
12	PICCOS(IN SET UP)	STUDY	PI (Derby)	2025
11	DETECT 2	STUDY	PI (Derby)	2026
10	CONCEPT	INTERNATIONAL AUDIT	PI (Derby)	2024
9	LIFE AFTER WOMB CANCER	STUDY	PI (Derby)	2024
8	COVID CANCER SURG – ELECTIVE SURGERY RESILIANCE INDEX	INTERNATIONAL AUDIT	PI (Derby)	2021
7	PROTECTOR	STUDY	PI (Derby)	2021
6	COVID CANCER SURG	INTERNATIONAL AUDIT	PI (Derby) - Gynaecology	2021
5	COVID SURG WEEK	INTERNATIONAL AUDIT	Supervising consultant – Trainee led	2020
4	UKCOGS	NATIONAL AUDIT	PI (Derby)	2020
3	OVARIAN CANCER FEASABILITY AUDIT	NATIONAL AUDIT	Task force member	2019
2	STATEC	STUDY	Recruiter	2018
1	SHAPE	STUDY	Recruiter	2018

PUBLICATIONS

NATIONAL GUIDELINES (AUTHOR)

No.	Reference	Organisation	Year
2	British Gynaecological Cancer Society and British Menopause Society guidelines: Management of menopausal symptoms following treatment of gynaecological cancer	BGCS/BMS	2024
1	Management of unscheduled bleeding on hormone replacement therapy (HRT)	BGCS/BMS	2024

NATIONAL GUIDELINES (REVIEWER)

No.	Reference	Organisation	Year
4	Ovarian Cysts in Postmenopausal Women (Green-top Guideline No. 34) Minor update 2025	RCOG	2025
3	British Gynaecological Cancer Society (BGCS) uterine cancer guidelines: Recommendations for practice	BGCS	2022
2	The use of biomarkers to stratify surgical care in women with ovarian cancer Scientific Impact Paper No. 69	RCOG	2022
1	British Gynaecological Cancer Society (BGCS) cervical cancer guidelines: Recommendations for practice	BGCS	2020

JOURNAL ARTICLES

No.	Reference	Year
30	Nayab et al. Comparative Analysis of FDG - PET Versus CT/MRI in Staging and Management of Advanced - stage Cervical Cancer Anticancer Research 45	2025
29	Ashmore et al, The Peritoneal Cancer Index as a Predictor of Cytoreductive Surgery Outcomes and Heatmapping of Ovarian Cancer Distribution: A Retrospective Analysis Cancers 2025, 17(17), 2790	2025
28	Sia J, Lane EF, Fierheller CT, et al. Estimands for Clinical Effectiveness of Risk-Reducing Early Salpingectomy in Women With High Risk of Ovarian Cancer. JAMA Netw Open. 2025;8(9):e2532195.	2025
27	Phillips A. Bowen Rm Wells M, McNeish I, Sundar S Key clinical findings from the IMPROVE-UK quality improvement projects: an overview BMJ Open Quality Feb 2025	2025
26	Ashmore A.A et Al Value of endometrial biopsy in patients with hysteroscopically atrophic endometrium in patients with postmenopausal bleeding Archives of Gynecology and Obstetrics (2025)	2025

- 26 Ashmore, A.A., Balasubramanian, B., Phillips, A. et al. Bioinformatic and experimental data pertaining to the role of the NLRP3 inflammasome in ovarian cancer. *J Cancer Res Clin Oncol* 150, 488 (2024).
<https://doi.org/10.1007/s00432-024-05988-9> 2024
- 25 Gaba F, et al. Surgical decision making in premenopausal BRCA carriers considering risk- reducing early salpingectomy or salpingo- oophorectomy: a qualitative study *J Med Genet* 2022;59:122–132. doi:10.1136/jmedgenet-2020-107501 2022
- 24 Taylor A et Al British Gynaecological Cancer Society and British Menopause Society guidelines: Management of menopausal symptoms following treatment of gynaecological cancer *Post Reproductive Health* 2024
- 33 Ashmore A, et al. Regular follow-up with cervical cytology is of questionable value following surgical treatment of microinvasive cervical cancer. *EJOG*. 296. May 2024 2024
- 32 Susan Addley, Mark McGowan, Harriet Crossland, Amoy Johnson, Viren Asher, Anish Bali, Summi Abdul, Andrew Phillips Neo-adjuvant chemotherapy does not reduce surgical complexity nor the accuracy of intra-operative visual assessment of disease in advanced ovarian cancer *EJSO* 49(2023) 2023
- 31 Collins A, Phillips A. Sentinel lymph node mapping in the modern management of gynaecological malignancy. *The Obstetrician & Gynaecologist* 2023; <https://doi.org/10.1111/tog.12872> 2023
- 30 Sundar, S.; Nordin, A.; Morrison, J.; Wood, N.; Ghaem-Maghami, S.; Nieto, J.; Phillips, A.; Butler, J.; Burton, K.; Gornall, R.; et al. British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer. *Cancers* 2023, 15, 337. <https://doi.org/10.3390/cancers15020337> 2023
- 29 Mark McGowan, James Davies, Susan Addley, Laura Honeyman, Shilpa Kolhe, Andrew Phillips Does the presence of single compared to multiple endometrial polyps alter the risk of cancer in post-menopausal women? *European Journal of Obstetrics & Gynecology and Reproductive Biology* Volume 279, December 2022, Pages 118-121 2022
- 28 NIHR Global Health Unit on Global Surgery, COVIDSurg Collaborative Elective surgery system strengthening: development, measurement, and validation of the surgical preparedness index across 1632 hospitals in 119 countries *Lancet* 2022
- 27 Mark McGowan, Susan Addley, James Davies, Summi Abdul, Viren Asher, Anish Bali, William Dudill & Andrew Phillips (2022): Does the character of the hospital of primary management influence outcomes in patients treated for presumed early stage endometrial cancer and atypical endometrial hyperplasia: a comparison of outcomes from a cancer unit and cancer centre, *Journal of Obstetrics and Gynaecology*, DOI: 0.1080/01443615.2022.2126753 2022
- 26 K. G. Smallwood, S. Crockett, V. Huang, V. Cullimore, J. Davies, G. Satti & A Phillips (2022): Changing patterns of referral into a family history clinic and 2022

- detection of ovarian cancer: a retrospective 10-year review, *Journal of Obstetrics and Gynaecology*, DOI:10.1080/01443615.2022.2111253
- 25 CovidSurgCollab Outcomes of gynecologic cancer surgery during the COVID-19 pandemic: an international, multicenter, prospective CovidSurg-Gynecologic Oncology Cancer study AJOG 2022
 - 24 CovidSurgCollab. Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study *Lancet* Nov 2021 2021
 - 23 Susan Addley, Viren Asher, Rathy Kirke, Anish Bali, Summi Abdul, Andrew Phillips What are the implications of radiologically abnormal cardiophrenic lymph nodes in advanced ovarian cancer? An analysis of tumour burden, surgical complexity, same-site recurrence and overall survival *EJSO* June 2022 2022
 - 22 Addley S, McGowan M, Asher V, Bali A, Abdul S, Cullimore V, Crossland H, Phillips A. Lactate Is a Reliable Predictor of ICU Length of Stay Following Ultra-radical Ovarian Cancer Surgery. *Anticancer Res.* 2022 Apr;42(4):1979-1986. doi: 10.21873/anticanres.15676. PMID: 35347018. 2022
 - 21 CovidSurg Collaborative Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study *Lancet Oncology* 2021; 22: 1507–17 2021
 - 20 Richardson, Persic, Watson, Phillips SAFETY OF HORMONE REPLACEMENT THERAPY IN WOMEN WITH A HISTORY OF CERVICAL ADENOCARCINOMA *Post reproductive health* 13/July/2021 2021
 - 19 Boyle W, Phillips A., Vella J., et al Gastrointestinal Stromal Tumors (GISTs) as Incidental Findings in Gynecological Surgery. *International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists* volume Publish Ahead of Print 1/4/2021 2021
 - 18 Keziah Element, Viren Asher, Anish Bali, Summi Abdul, Dhanny Gomez, Samson Tou, Richard Curtis, James Low & Andrew Phillips (2021) Poor anaerobic threshold and VO2 max recorded during cardiopulmonary exercise testing (CPET) prior to cytoreductive surgery in advanced (stage 3/4) ovarian cancer (AOC) is associated with suboptimal cytoreduction but does not preclude maximum effort cytoreduction, *Journal of Obstetrics and Gynaecology*, DOI: 10.1080/01443615.2021.1893669 2021
 - 17 Dai Da, Balega J, Sundar S, Kehoe S, Elattar A, Nevin J, Phillips A, Singh K Hypoalbuminaemia in Advanced Ovarian Cancer (AOC): Primary or Interval Surgery?: A retrospective study *Journal of Investigative Surgery* 2020 Oct 6;1-6. doi: 10.1080/08941939.2020.1827314 2020
 - 16 Davies J, Abdul S, Asher A, Bali A, Phillips A Does the performance of splenectomy as part of cytoreductive surgery carry a worse prognosis than in patients not receiving splenectomy? A propensity score analysis and review of the literature. *Journal of Investigative Surgery* 2020 Dec 28;1-7. doi: 10.1080/08941939.2020.1824043 2020
 - 15 Glover O, Asher V, Bali, A, Abdul S, Collins A and Phillips A Primary and Interval 2020

Debulking Surgery Provide Similar Survival and Platinum Sensitivity Outcomes in Advanced Ovarian Cancer. A retrospective study. *Anticancer research* 2020 Jul;40(7):3925-3929. doi: 10.21873/anticancer.14383

- 14 Searle G; Pounds R; Phillips A; Kehoe S; Balega J; Singh K Prolonged interruption of chemotherapy in patients undergoing delayed debulking surgery for advanced high grade serous ovarian cancer is associated with a worse prognosis *Gynecologic Oncology* 2020 Jul;158(1):54-58. doi: 10.1016/j.ygyno.2020.04.048
- 13 Kumar S, Srinivasan A, Phillips A, Madhupriya, R, Pascoe J, Nevin J, Elattar A, Balega J, Sundar S, Kehoe S, Singh K *Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?* *Journal of Obstetrics and Gynaecology* 2020 Aug;40(6):849-855. doi: 10.1080/01443615.2019.1674264
- 12 Richardson, Ayres, Cust, Phillips *Hormone replacement therapy following treatment of gynaecological malignancies* *The Obstetrician and Gynaecologist* 2019;21:291-8
- 11 Phillips A, Kehoe S, Singh K, Elattar A, Nevin J, Balega J, Pounds R, El-Modir A, Pascoe J, Fernando I, Sundar S *Socioeconomic differences impact overall survival in advanced ovarian cancer (AOC) prior to achievement of standard therapy.* *Archives of Gynecology and Obstetrics* 2019 Nov;300(5):1261-1270
- 10 Phillips A, Sundar S, Singh K, Pounds R, Nevin J, Kehoe S, Balega J, Elattar A. *The NICE classification for "Ultra-radical (extensive) surgery for advanced ovarian cancer" guidance does not meaningfully predict post-operative complications: a cohort study.* *BJOG: An International Journal of Obstetrics and Gynaecology* (2019) 126(1)
- 9 Pounds R, Phillips A, Kehoe S, Nevin J, Sundar S, Elattar A, Teo HG, Singh K, Balega J *Diaphragm disease in advanced ovarian cancer: predictability of pre-operative imaging and safety of surgical intervention* *European Journal of Obstetrics, Gynaecology and Reproductive biology* 226 (2018) 47-53
- 8 Phillips A, Sundar S, Singh K, Nevin J, Elattar A, Kehoe S, Balega J *Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer.* *European Journal of Surgical Oncology* 2018 44(6) 760-765
- 7 Phillips, A., Sundar, S., Pounds, R., Elattar, A., Nevin, J., Kehoe, S., Balega, J. and Singh, K. *Has the 'paradigm shift' in the management of advanced ovarian, tubal and primary peritoneal cancer altered the locations of recurrence?* *Eur J Gynaecol Oncol* 2018 39(3) 365-371
- 6 Phillips, A., Balega, J., Nevin, J., Singh, K., Elattar, A., Kehoe, S. and Sundar, S. *Reporting 'Denominator' data is essential for benchmarking and quality standards in ovarian cancer* *Gynecol Oncol* 146 (2017) 94-100
- 5 Phillips, A., Singh, K., Pounds, R., Sundar, S., Kehoe, S., Nevin, J., Elattar, A. and Balega, J. *Predictive value of the Age-adjusted Charlston Co-morbidity Index on peri-operative complications, adjuvant chemotherapy usage and survival in patients undergoing debulking surgery after neo-adjuvant chemotherapy*

for advanced epithelial ovarian cancer J Obstet Gynecol 2017 Nov;37(8):1070-1075

- 4 Phillips, A., Pounds, R., Balega, J. and Singh, K. *Histopathological correlation of splenic disease with radiological and surgical findings: should we incorporate splenectomy into standard procedures for disseminated Mullerian adenocarcinoma?* Eur J Gynaecol Oncol (2016) 37(5):678-684 2016
- 3 Kehoe, S., Fares, R. and Phillips, A. *Ovarian cancer: Is chemotherapy before surgery the way forward?* Int J Endocr Oncol (2016) 3(1):5-12 2016
- 2 Phillips, A. and Finch, L., Acheson, N., Dix, P. and Berry, C. *An evaluation of the effects of a service change from epidurals to rectus sheath catheters on postoperative pain* J Obstet Gynecol (2013) 33:502-504 2013
- 1 Hannemann, M. and Phillips, A. *Endometrial Hyperplasia: A Clinician's Review* Obstetrics, Gynaecology and Reproductive Medicine (2010) 20(4):116-120 2010

RESEARCH/NATIONAL AND INTERNATIONAL AUDITS LISTED AS CONTRIBUTOR

No.	Reference	Year
1	Gaba F, Robbani S, Singh N, et al Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial International Journal of Gynecologic Cancer Published Online First: 08 September 2020. doi: 10.1136/ijgc-2020-001541	2020

PUBLISHED ABSTRACTS

No.	Reference	Year
25	Mahwish Nayab et al. Staging re-imag(in)ed: FDG PET is not an extra test, but a vital decision-maker in advanced cervical cancer BJOG: Int J Obstet Gy, 132 (Supp)72 BGCS—ASM 2025 London Publication of Abstracts	2025
34	Mahwish Nayab et al. Doesn't describe it, doesn't exclude it: Non-specialist ultrasound is of limited value in Advanced Cervical cancer (AdvCC) BJOG: Int J Obstet Gy, 132 (Supp)71 BGCS—ASM 2025 London Publication of Abstracts	2025
33	Mahwish Nayab et al. Comparative analysis of PET and CT imaging for staging the stage 2–3 Cervical cancer: Impact on survival BJOG: Int J Obstet Gy, 132 (Supp)47 BGCS—ASM 2025 London Publication of Abstracts	2025
32	Ayisha Ashmore et al. Identifying an in vitro model for NLRP3 inflammasome activation BJOG: Int J Obstet Gy, 132 (Supp)24 BGCS—ASM 2025 London Publication of Abstracts	2025
31	Ayisha Ashmore et al. The peritoneal cancer index as a predictor of cytoreductive surgery and ovarian cancer distribution: A retrospective analysis with heatmap visualisation BJOG: Int J Obstet Gy, 132 (Supp) 23-24 BGCS—ASM 2025 London Publication of Abstracts	2025
30	S. Addley, H. Crossland, A. Bali, S. Abdul, V. Asher, A. Phillips Recto-sigmoid resection confers no PFS or OS advantage over POD peritonectomy in	2024

completely cytoreduced advanced ovarian cancer (2024), BGCS ASM 2024. BJOG: Int J Obstet Gy, 131: 3-68. <https://doi.org/10.1111/1471-0528.17941>

- 29 Ashmore A, P.D. Garcia, A. Phillips, V. Asher, A. Bali, P.O.Moran, R. Khan NLRP3 inflammasome in ovarian cancer: bioinformatic expression analysis and validation in theSKOV3 cell line and tumour ascites. (2024), BGCS ASM 2024. BJOG: Int J Obstet Gy, 131: 3-68. <https://doi.org/10.1111/1471-0528.17941> 2024
- 28 Ashmore A, A. Alao , A. Hibbard, L. Burchnall , N. Menic ,S. Abdul , V. Asher, A. Bali, S. Kohle, A. Phillips Is there any value of performing endometrialbiopsy in women with postmenopausal bleeding withvisible atrophic endometrium at hysteroscopy? (2024), BGCS ASM 2024. BJOG: Int J Obstet Gy, 131: 3-68. <https://doi.org/10.1111/1471-0528.17941> 2024
- 27 Collins A, M. El-Naggar, M. Persic, S. Addley, V. Asher,S. Abdul, A. Bali, A. Phillips Diagnosis and management of brainmetastases in ovarian cancer: 6-year experience from alarge UK gynaecological cancer centre 2024. BJOG: Int J Obstet Gy, 131: 3-68. <https://doi.org/10.1111/1471-0528.17941> 2024
- 26 C. Hill, S. Foster, K. Berrington, E. Stokes, A. Phillips, V. Asher No one left behind: Development of amultidisciplinary operational team meeting tostreamline perioperative care of women undergoingcytoreductive surgery 2024. BJOG: Int J Obstet Gy, 131: 3-68. <https://doi.org/10.1111/1471-0528.17941> 2024
- 25 C. Hill, S. Foster, K. Berrington, E. Stokes, A. Phillips, V. Asher Introducing Clinical Nurse Specialist(CNS) led triage into the 2ww pathway: The DerbyGynaecological Cancer Centre (DGCC) experience 2024. BJOG: Int J Obstet Gy, 131: 3-68. <https://doi.org/10.1111/1471-0528.17941> 2024
- 24 E. Marshall, S. Abdul, S. Addley, M. Persic, R. Mohammed, V. Asher, A. Bali, A. Phillips Hysteroscopy significantly increases theproportion of patients having successful brachytherapyinsertion in advanced cervical cancer 2024. BJOG: Int J Obstet Gy, 131: 3-68. <https://doi.org/10.1111/1471-0528.17941> 2024
- 23 M. Okba, A. Phillips, V. Asher, S. Abdul, A. Bali,S. Addley Incompletely excised pre-malignant vulvalpathology does not confer increased vulval cancerrecurrence risk: 19-year experience from a UK cancercentre 2024. BJOG: Int J Obstet Gy, 131: 3-68. <https://doi.org/10.1111/1471-0528.17941> 2024
- 22 Addley S, Bali A, Asher V, et al552 Feasibility of diaphragmatic surgery for advanced ovarian cancer: a single institution analysis series International Journal of Gynecologic Cancer 2021;31: A245-A246 2022
- 21 Addley S, Bali A, Asher V, et al552 Uterine serous carcinoma mimicking advanced ovarian cancer. Are there clues to pre-operative diagnostic differentiation? A mini case series International Journal of Gynecologic Cancer 2021;31:A248-A249. 2021
- 20 Honeyman L, Davies J, Kolhe S, et al780 Frequency and duration of post-menopausal bleeding – risk stratification for endometrial cancer International Journal of Gynecologic Cancer 2021;31:A122. 2021
- 19 Davies J, Hartshorn K, Honeyman L, et al453 External validation of the Norwich DEFAB score for up-front prediction of endometrial cancer International Journal of Gynecologic Cancer 2021;31:A96. 2021

- 18 Addley S, Bali A, Asher V, et al⁵⁴³ Correlation between CT, intra-operative assessment and final histopathology in detecting diaphragmatic disease in advanced ovarian cancer. 61 cases *International Journal of Gynecologic Cancer* 2021;31:A247-A248. 2021
- 17 Davies J, Honeyman L, Hartshorn K, et al⁴⁷³ The significance of single versus multiple polyps at hysteroscopy in post menopausal bleeding *International Journal of Gynecologic Cancer* 2021;31:A68. 2021
- 16 Mantrali I, Phillips A, Abdul S, et al⁷⁷⁴ Changes in theatre utilisation following implementation and establishment of maximal effort surgical philosophy for advanced epithelial ovarian cancer *International Journal of Gynecologic Cancer* 2021;31:A272-A273. 2021
- 15 Watson L, Hall T, Asher V, et al³⁴⁷ Outcomes of patients undergoing extremely high complexity surgery (EHCS) for advanced ovarian cancer, a single centre review of practice *International Journal of Gynecologic Cancer* 2020;30:A142. 2020
- 14 Watson L, Hatfield T, Lavender G, et al²¹⁴ No socioeconomic differences in overall survival seen in patients with advanced ovarian cancer where parity of access to treatment and cytoreductive outcomes can be achieved *International Journal of Gynecologic Cancer* 2020;30:A89-A90. 2020
- 13 Richardson A, Watson L, Persic M, et al¹³⁴ HRT is not detrimental to survival in women diagnosed with stage 1B–2B (FIGO 2009) adenocarcinomas of the cervix aged less than 50 *International Journal of Gynecologic Cancer* 2020;30:A59-A60. 2020
- 12 Smallwood K, Phillips A, Asher V, et al³⁷⁵ The changing nature of referral pathways for risk reducing salpingo-oophorectomy in a UK cancer centre *International Journal of Gynecologic Cancer* 2020;30:A156. 2020
- 11 Smallwood K, Huang V, Phillips A, et al¹⁰¹ Oncological outcomes following risk reducing bilateral salpingo-oophorectomy in women deemed high risk for ovarian cancer *International Journal of Gynecologic Cancer* 2020;30:A48-A49. 2020
- 10 Shaban A, Abdul S, Asher V, et al EP1152 Prevalence of occult cancer in biopsy proven VIN3 and dVIN in lesions suspicious and not suspicious of malignancy *International Journal of Gynecologic Cancer* 2019;29:A599. 2019
- 9 K Element, P Mehrotra, V Asher, A Bali, S Abdul, J Low, R Curtis, S Tou, D Gomez and A Phillips EP953 Poor AT and VO2 max recorded during cardiopulmonary exercise testing (CPET) prior to cytoreductive surgery in advanced (Stage 3/4) ovarian cancer (AOC) is associated with suboptimal cytoreduction but does not preclude maximum effort cytoreduction *International Journal of Gynecologic Cancer* 2019;29:A508. 2019
- 8 Asher V, Abdul S, Tou S, et al EP785 Does progression free survival (PFS), overall survival (OS) or platinum sensitive interval (PSI) differ in patients undergoing intermediate/high complexity surgery for advanced ovarian cancer (AOC) when treated by primary (PDS) or Interval (IDS) debulking surgery? *International Journal of Gynecologic Cancer* 2019;29:A434. 2019

7	Dai D, Balega J, Sundar S, et al EP986 Hypoalbuminaemia in advanced ovarian cancer (AOC): primary or interval surgery? International Journal of Gynecologic Cancer 2019;29:A522.	2019
6	Hirsi-Farah S, Kerai S, Abdul S, et al EP382 Regular follow up with cervical/vault cytology is of questionable value in patients treated for microinvasive cervical cancer International Journal of Gynecologic Cancer 2019;29:A257.	2019
5	Morris C, Davies J, Asher V, et al EP249 Survival in 1B1 cervical cancer treated radical hysterectomy via open or minimal access approaches at a medium sized cancer centre in the united kingdom International Journal of Gynecologic Cancer 2019;29:A197.	2019
4	Davies J, Asher V, Bali A, et al EP954 Impact of Splenectomy on survival in advanced ovarian cancer (AOC) in a propensity matched cohort International Journal of Gynecologic Cancer 2019;29:A508-A509.	2019
3	Chipwete, S.E., Guttikonda, S., Phillips, A., Balega, J., Moss, E. and Singh, K. Histological diagnosis of rectosigmoid resections performed in ovarian cancer surgery. BJOG (2016) 123:108	2016
2	Phillips, A. and Rajasri, A. Focused ultrasound training for speciality registrars: a simple solution to curriculum difficulties Arch Dis Child Fetal Neonatal Ed (2011) 96:Fa138	2011
1	Phillips, A., O'Donovan, O., Walters, H. and Taylor, M.J. An on-line video education programme for couple with twins: A qualitative study Arch Dis Child Fetal Neonatal Ed (2010);95 (Suppl X) Fa20	2010

LETTERS

No.	Reference	Year
5	Phillips, A and Asher, V Denominator Based Studies Need Full Disclosure of the Origins of Patients Treated Ann Surg Oncol 31 st July 2019	2019
4	Phillips, A. <i>Re: Increased mortality associated with weekend hospital admission: a case for expanded seven-day services?</i> BMJ 6 th September 2015	2015
3	Phillips, A. <i>Free speech and professional duty</i> BMJ 14 th February 2011	2011
2	Phillips, A., and Bhatnagar, R. <i>Effect of high flow oxygen on mortality in COPD; is such an RCT ethically acceptable?</i> BMJ 3 rd November 2010	2010
1	Phillips, A. <i>Don't be afraid to ask</i> BMJ News 4 th September 2010	2010

BOOK CHAPTERS

No.	Reference	Year
3	Addley A & Phillips A Non-serous and Rare Histologies of Ovarian Cancer Case-Based Gynecological Oncology 2024 Springer	2024

- 2 Phillips A & Burrows B *Multidisciplinary Decision Making in Gynaecology: Guidance, Conduct and Legalities in Gynecological Oncology: Basic Principles and Clinical Practice* 2022 Springer
- 1 Phillips, A. and Acheson, N. *Basic Epidemiology in Gynaecological Oncology for the MRCOG and Beyond, 2nd Edition* 2010 RCOG Press, London

CHAired ACADEMIC SESSIONS

Session	Conference	Location	Date
Gynaecological Cancers from Childhood to Menopause	BGCS ASM	Liverpool	12/6/24
Hormone replacement therapy after gynaecological cancer treatment	BGCS ASM	Cheltenham (Virtual)	13/5/21

PEER REVIEWER

No.	Reference	Year
8	ECOG	2024→Present
7	The Obstetrician and Gynaecologist	2019→Present
6	BJOG: (An international journal of Obstetrics and Gynaecology)	2018→Present
5	Gynecologic Oncology	2017→Present
4	European Journal of Gynaecological Oncology	2020
3	Dove Press: OncoTargets and Therapy	2018
2	Journal of Obstetrics and Gynaecology	2014-2015
1	Journal of Public health	2012-2013

ORAL PRESENTATIONS

INTERNATIONAL

No.	Title	Location	Year
1	Ultraradical surgery for ovarian cancer: Light and Shadows. (Invited Speaker) Perinthalmanna Obs & Gynae Society Annual Meeting*	Virtual, Kerala, India	2020

*invited speaker

NATIONAL

No.	Title	Location	Year
8	Stage IV Ovarian Cancer – Surgical Approach	BGCS National Training Day	2025
7	BGCS Treasurers report as AGM	BGCS ASM	2003-205
6	S. Addley, H. Crossland, A. Bali, S. Abdul, V. Asher, A. Phillips Recto-sigmoid resection confers no PFS or OS advantage over POD peritonectomy in completely cytoreduced advanced ovarian cancer §	BGCS	2024
5	IMPROVE-UK Pilot sites*	UKGOM	2023
4	Chair BGCS session – HRT and Gynaecological Cancer	BGCS	2021
3	Gynaecological Oncology for the MRCOG*	BGCS Webinar	2021
2	The age-adjusted Charlston comorbidity index predicts survival in patients undergoing debulking surgery after neo-adjuvant chemotherapy for advanced epithelial ovarian cancer	BGCS	2016
1	Histological diagnosis of rectosigmoid resections performed in ovarian cancer surgery§	BGCS	2016

*invited speaker §presented by co-author

REGIONAL

No.	Title	Location	Year
10	Why Gynaecological Oncologists need to do (know) everything! *	BMOGS	2021
9	Non-Operated patients and the total patient denominator	East Midlands Gynae-Onc Symposium	2019
8	Type 2 Endometrial cancers and MMMT*	East Midlands Gynae-Onc Symposium	2018
7	A fellow's experience of ovarian cancer surgery at the	East Midlands Gynae-	2016

	Pan-Birmingham Gynaecological Cancer Centre: 5 observations from my last 2 years*	Onc Symposium	
6	Type 2 Endometrial cancers and MMT*	East Midlands Gynae-Onc Symposium	2015
5	HPV, cervical cancer and the vaccination programme*	East Midlands Gynae-Onc Symposium	2014
4	Variation in clinician technique when using the Pipelle endometrial sampler	East Midlands Gynae-Onc Symposium	2014
3	Obstetric disasters for the non-Obstetrician*⌘	BASICS South West	2013
2	How should we follow-up patients with ovarian cancer?	East Midlands Gynae-Onc Symposium	2011
1	Medical management of ectopic pregnancy in Peninsula deanery: a multi-centre retrospective case note review§	SWOGS	2009

*invited speaker ⌘prize awarded §presented by co-author

LOCAL

No.	Title	Location	Year
6	Surgical Division Day Ovarian Cancer at RDH	Royal Derby Hospital	2020
5	Malignancies of the Female Genital Tract	Royal Derby Hospital	2019
4	Reducing the risk of ovarian cancer in BRCA carriers	Royal Derby Hospital	2019
3	Advanced Ovarian Cancer outcomes 2018 ITU presentation	Royal Derby Hospital	2018
2	Morbidity/Mortality Quarterly Review	Birmingham City Hospital	2015
1	Ultra-radical NICE compliance audit	Birmingham City Hospital	2014

POSTER PRESENTATIONS

INTERNATIONAL

No.	Title	Location	Year
26	The reliability of pre-operative CT imaging in predicting cardio-phrenic lymph node involvement prior to both PDS and DDS for advanced ovarian cancer. Data from a UK cancer centre	SGO, Phoenix	2022
25	Feasibility of diaphragmatic surgery for advanced ovarian cancer: a single institution analysis	ESGO	2021
24	Uterine serous carcinoma mimicking advanced ovarian cancer. Are there clues to pre-operative diagnostic differentiation? A mini case series	ESGO	2021
23	Frequency and duration of post-menopausal bleeding – risk stratification for endometrial cancer	ESGO	2021
22	External validation of the Norwich DEFAB score for up-front prediction of endometrial cancer	ESGO	2021
21	Correlation between CT, intra-operative assessment and final histopathology in detecting diaphragmatic disease in advanced ovarian cancer. 61 cases	ESGO	2021
20	Changes in theatre utilisation following implementation and establishment of maximal effort surgical philosophy for advanced epithelial ovarian cancer	ESGO	2021
19	The significance of single versus multiple polyps at hysteroscopy in post menopausal bleeding	ESGO	2021
18	Oncological outcomes following risk reducing bilateral salpingo-oophorectomy in women deemed high risk for ovarian cancer.	IGCS	2020
17	HRT is not detrimental to survival in women diagnosed with stage 1B–2B (FIGO 2009) adenocarcinomas of the cervix aged less than 50	IGCS	2020
16	No socioeconomic differences in overall survival seen in patients with advanced ovarian cancer where parity of access to treatment and cytoreductive outcomes can be achieved.	IGCS	2020
15	Outcomes of patients undergoing extremely high complexity surgery (EHCS) for advanced ovarian cancer, a single centre review of practice.	IGCS	2020
14	The changing nature of referral pathways for risk reducing salpingo-oophorectomy in a UK Cancer Centre.	IGCS	2020
13	Survival in 1B1 cervical cancer treated radical hysterectomy via open or minimal access approaches at a medium sized cancer centre in the United Kingdom	ESGO	2019

12	Prevalence of occult cancer in biopsy proven VIN3 and dVIN in lesions suspicious and not suspicious of malignancy	ESGO	2019
11	Poor AT and VO2 max recorded during Cardiopulmonary Exercise Testing (CPET) prior to cytoreductive surgery in advanced (Stage 3/4) ovarian cancer (AOC) is associated with suboptimal cytoreduction but does preclude maximum effort cytoreduction.	ESGO	2019
10	Regular follow up with cervical/vault cytology is of questionable value in patients treated for microinvasive cervical cancer.	ESGO	2019
9	Does Progression Free Survival(PFS), Overall Survival(OS) or platinum sensitive interval(PSI) differ in patients undergoing intermediate/high complexity surgery for advanced ovarian cancer(AOC) when treated by primary (PDS) or Interval (IDS) debulking surgery?	ESGO	2019
8	Impact of Splenectomy on survival in advanced ovarian cancer (AOC) in a propensity matched cohort. Hypoalbuminaemia in Advanced Ovarian Cancer (AOC): Primary or Interval Surgery? A retrospective study	ESGO	2019
7	Hypoalbuminaemia in Advanced Ovarian Cancer (AOC): Primary or Interval Surgery? A retrospective study	ESGO	2019
6	Reporting Denominator Data Is Essential For Benchmarking And Quality Standards In Advanced Ovarian Cancer (AOC)	ESGO	2017
5	Complete Cytoreduction After Six Cycles Of Neo-Adjuvant Chemotherapy (NACT) Confers A Survival Benefit In Advanced Ovarian Cancer (AOC)	ESGO	2017
4	Histological diagnosis of rectosigmoid resections performed in ovarian cancer surgery	RCOG World Congress	2016
3	Digitally guided endometrial sampling: an alternative to anaesthesia for the assessment of increased endometrial thickness in high operative risk patients	ESGO	2013
2	Role of ultrasound in the detection of recurrent ovarian cancer	ESGO	2013
1	Analgesic requirements, length of stay and immediate complications in vaginal mesh repairs versus traditional anterior and poster colporrhaphy: a retrospective pilot study	International Continence Society	2009

NATIONAL

No.	Title	Location	Year
63	Mahwish Nayab et al. Staging re-imag(in)ed: FDG PET is not an extra test, but a vital decision-maker in advanced	BGCS	2025

	cervical cancer		
62	Mahwish Nayab et al. Doesn't describe it, doesn't exclude it: Non-specialist ultrasound is of limited value in Advanced Cervical cancer (AdvCC)	BGCS	2025
61	Mahwish Nayab et al. Comparative analysis of PET and CT imaging for staging the stage 2–3 Cervical cancer: Impact on survival	BGCS	2025
60	Ayisha Ashmore et al. Identifying an in vitro model for NLRP3 inflammasome activation	BGCS	2025
59	Ayisha Ashmore et al. The peritoneal cancer index as a predictor of cytoreductive surgery and ovarian cancer distribution: A retrospective analysis with heatmap visualisation	BGCS	2025
58	Ashmore A, P.D. Garcia, A. Phillips, V. Asher, A. Bali, P.O.Moran, R. Khan NLRP3 inflammasome in ovarian cancer: bioinformatic expression analysis and validation in theSKOV3 cell line and tumour ascites.	BGCS	2024
57	Ashmore A, A. Alao , A. Hibbard, L. Burchnall , N. Menic ,S. Abdul , V. Asher, A. Bali, S. Kohle, A. Phillips Is there any value of performing endometrialbiopsy in women with postmenopausal bleeding withvisible atrophic endometrium at hysteroscopy?	BGCS	2024
56	Collins A, M. El-Naggar, M. Persic, S. Addley, V. Asher,S. Abdul, A. Bali, A. Phillips Diagnosis and management of brain metastases in ovarian cancer: 6-year experience from alarge UK gynaecological cancer centre	BGCS	2024
55	C. Hill, S. Foster, K. Berrington, E. Stokes, A. Phillips, V. Asher No one left behind: Development of a multidisciplinary operational team meeting to streamline perioperative care of women undergoing cytoreductive surgery	BGCS	2024
54	C. Hill, S. Foster, K. Berrington, E. Stokes, A. Phillips, V. Asher Introducing Clinical Nurse Specialist(CNS) led triage into the 2ww pathway: The Derby Gynaecological Cancer Centre (DGCC) experience	BGCS	2024
53	E. Marshall, S. Abdul, S. Addley, M. Persic, R. Mohammed, V. Asher, A. Bali, A. Phillips Hysteroscopy significantly increases theproportion of patients having successful brachytherapyinsertion in advanced cervical cancer	BGCS	2024
52	M. Okba, A. Phillips, V. Asher, S. Abdul, A. Bali,S. Addley Incompletely excised pre-malignant vulval pathology does not confer increased vulval cancer recurrence risk: 19-year experience from a UK cancer centre	BGCS	2024

51	Dr Susan Addley ¹ , Dr Emma Midgley ¹ , Dr Tabitha Mohanarajah ¹ , Mr Viren Asher ¹ , Mr Anish Bali ¹ , Mr Summi Abdul ¹ , Mr Andrew Phillips VTE during neo-adjuvant chemotherapy for advanced ovarian cancer significantly delays interval cytoreductive surgery. Data from a large UK cancer centre	BGCS	2023
50	Miss Kathryn Smallwood ¹ , Mr Mohamed Okba ¹ , Dr Rand Hawari ² , Mrs Samantha Crockett ² , Dr José Pereira Marques Leal ² , Mr Oliver Ossowski ³ , Mr Andrew Phillips ¹ Homologous Recombination Deficiency (HRD) testing in advanced ovarian cancer: Can we improve our testing pathway?	BGCS	2023
49	Dr Mohamed Okba ¹ , Ms Susan Addley ¹ , Mr Andrew Phillips ¹ Utilisation of gynaecological-oncology surgeons and review of patient outcomes in the emergency gynaecological surgery setting. A retrospective audit over a 24 month period from a UK cancer centre	BGCS	2023
48	Dr Susan Addley ¹ , Dr Mark McGowan ¹ , Mr Viren Asher ¹ , Mr Anish Bali ¹ , Mr Summi Abdul ¹ , Dr Victoria Cullimore ¹ , Dr Harriet Crossland ¹ , Mr Andrew Phillips ¹ Development and persistence of peri-operative hyperlactaemia is associated with significantly longer ICU, HDU and total inpatient length of stay following maximal effort cytoreductive surgery for advanced ovarian cancer	BGCS	2023
47	Dr Susan Addley ¹ , Mr Viren Asher ¹ , Dr Rathy Kirke ¹ , Mr Anish Bali ¹ , Mr Summi Abdul ¹ , Mr Andrew Phillips ¹ Radiologically-suspicious cardiophrenic lymph nodes are a reliable predictor of tumour burden, upper abdominal involvement and surgical complexity score in advanced ovarian cancer – without impacting overall survival. Data from a large UK cancer centre over a 44 month period.	BGCS	2023
46	Dr Susan Addley ¹ , Mr Viren Asher ¹ , Dr Rathy Kirke ¹ , Mr Anish Bali ¹ , Mr Summi Abdul ¹ , Mr Andrew Phillips ¹ Cardiophrenic lymph node dissection of radiologically suspicious nodes does not improve overall survival at maximal effort cytoreductive surgery for advanced ovarian cancer. Provisional data from a large UK cancer centre.	BGCS	2023
45	Dr Jose Pereira Marques Leal ¹ , Dr Kimberly Bourne ¹ , Dr Susan Addley ¹ , Mr Andrew Phillips ¹ Low-pressure pneumoperitoneum omits the need for spinal anaesthetic at TLH in high-risk endometrial cancer patients with no increase in post-operative pain scores or LOS. Data from a UK cancer centre.	BGCS	2023
44	Diagnostic accuracy of upper abdominal procedures performed at maximal cytoreductive surgery for advanced ovarian cancer - a comparison of primary and	BGCS	2022

	delayed debulking. 232 consecutive cases over a 7 year period from a large UK cancer centre		
43	The completeness and legibility of gynaecology oncology ward-round documentation in a large UK centre: an audit cycle and staff survey	BGCS	2022
42	Correlation between intra-operative suspicion of lymphatic involvement at maximal cytoreductive surgery for advanced ovarian cancer and final histopathology - comparing primary and delayed debulking outcomes. A review of 232 cases from a large UK cancer centre over a 7 year interval	BGCS	2022
41	Low-risk endometrial cancer: a comparison of survival outcomes in patients undergoing unit versus centre-led surgical management	BGCS	2022
40	The feasibility of radical debulking video-assisted thoracic surgery (VATS) in advanced ovarian cancer: A preliminary case from a UK cancer centre	BGCS	2022
39	Incidental findings of synchronous TCC in redundant ureteric stump in patient with early stage endometrial cancer and previous ipsi-lateral nephrectomy	BGCS	2022
38	Cervical cancer mimicking primary oesophageal cancer at presentation: A rare pattern of spread and the diagnostic challenges	BGCS	2022
37	The incidence of radiologically-diagnosed incisional hernia following maximal effort cytoreductive surgery for advanced ovarian cancer. A review of 114 cases over a 4 year period from a large UK cancer centre	BGCS	2022
36	Bowel surgery at primary and delayed debulking for advanced ovarian cancer: Diagnostic accuracy of intra-operative assessment of disease. Review of 232 cases from a large UK cancer centre over a 7 year interval	BGCS	2022
35	Compliance with BHIVA-recommended HIV testing at new diagnosis of cervical cancer in a large UK cancer centre	BSCCP	2022
34	Feasibility of diaphragmatic surgery for advanced ovarian cancer: a single institution analysis	BGCS	2021
33	Uterine serous carcinoma mimicking advanced ovarian cancer. Are there clues to pre-operative diagnostic differentiation? A mini case series	BGCS	2021
32	Frequency and duration of post-menopausal bleeding – risk stratification for endometrial cancer	BGCS	2021

31	External validation of the Norwich DEFAB score for up-front prediction of endometrial cancer	BGCS	2021
30	The significance of single versus multiple polyps at hysteroscopy in post menopausal bleeding	BGCS	2021
29	Correlation between CT, intra-operative assessment and final histopathology in detecting diaphragmatic disease in advanced ovarian cancer. 61 cases	BGCS	2021
28	Changes in theatre utilisation following implementation and establishment of maximal effort surgical philosophy for advanced epithelial ovarian cancer	BGCS	2021
28	Uterine serous carcinoma mimicking advanced ovarian cancer – are there any clues to pre operative diagnostic differentiation? A mini case series from a cancer centre	BGCS	2021
27	Collaborative surgery facilitates resection of retrohepatic/retrocaval nodal disease in advanced ovarian cancer (AOC). A Case report	BGCS	2021
26	Does the frequency or duration of post-menopausal bleeding (PMB) help stratify the risk of Endometrial Cancer in women undergoing hysteroscopy for PMB?	BGCS	2021
25	The significance of single versus multiple polyps at hysteroscopy in post menopausal bleeding.	BGCS	2021
24	Relevance of an ectropion in women presenting with Post-Menopausal Bleeding (PMB)	BGCS	2021
23	Correlation between preoperative imaging, intra operative assessment and final histopathology for diaphragmatic disease in advanced ovarian cancer: A review of 61 cases	BGCS	2021
22	Diaphragmatic surgery in advanced ovarian cancer: Evaluating the feasibility, morbidity and benefit in 74 consecutive cases over a 7 year period in a tertiary referral cancer centre	BGCS	2021
21	External Validation of the Norwich DEFAB score for up Front prediction of endometrial cancer.	BGCS	2021
20	Evaluating the impact of the COVID 19 pandemic on theatre efficiency in a large gynaecological oncology centre	BGCS	2021
19	Abdominal Tuberculosis Masquerading as Carcinomatosis: Not Difficult to Miss!	ASIT	2020
18	Poor AT and VO2 max recorded during Cardiopulmonary Exercise Testing (CPET) prior to cytoreductive surgery in	BGCS	2019

advanced (Stage 3/4) ovarian cancer (AOC) is associated with suboptimal cytoreduction but does preclude maximum effort cytoreduction. Regular follow up with cervical/vault cytology is of questionable

17	Regular follow up with cervical/vault cytology is of questionable value in patients treated for microinvasive cervical cancer.	BGCS	2019
16	Survival in 1B1 Cervical cancer treated radical hysterectomy via open or minimal access approaches at a medium sized cancer centre in the United Kingdom.	BGCS	2019
15	Does Progression Free Survival(PFS), Overall Survival(OS) or platinum sensitive interval(PSI) differ in patients undergoing intermediate/high complexity surgery for advanced ovarian cancer(AOC) when treated by primary (PDS) or Interval (IDS) debulking surgery?	BGCS	2019
14	Impact of Splenectomy on survival in advanced ovarian cancer (AOC) in a propensity matched cohort.	BGCS	2019
13	Incidence of occult cancer in biopsy proven VIN3 and dVIN in lesions suspicious and not suspicious of malignancy.	BGCS	2019
12	Hypoalbuminaemia in Advanced Ovarian Cancer (AOC): Primary or Interval Surgery? A retrospective study	BGCS	2019
11	Detection and management of disease recurrence in advanced ovarian cancer	BGCS	2016
10	Optimal cytoreduction is not the optimal surgery in patients receiving neoadjuvant chemotherapy in advanced ovarian cancer	BGCS	2016
9	Key performance indicators for ovarian debulking surgery at the Pan-Birmingham Gynaecological Cancer Centre	BGCS	2016
8	Locations of recurrent disease in advanced ovarian cancer at the Pan-Birmingham Gynaecological Cancer Centre	BGCS	2016
7	Histopathological correlation of splenic disease with radiological and surgical findings in disseminated Mullerian adenocarcinoma	BGCS	2016
6	Diaphragmatic disease in advanced ovarian cancer (AOC) at the Pan-Birmingham Gynaecological Cancer Centre (PBGCC): incidence, detection and treatment	BGCS	2016
5	Variation in clinician technique when using the Pipelle endometrial sampler	East Midlands Gynae-Onc	2014

4	Ovarian Cancer in Pregnancy: Diagnostic and Therapeutic Dilemma	Symposium SPROGS	2013
3	Focused ultrasound training for specialty registrars: a simple solution to curriculum difficulties	BMFMS	2011
2	Comparison of the use of rectus sheath catheters with epidurals following midline laparotomy for gynaecological cancer as part of an enhanced recovery program [⌘]	Enhanced Recovery	2011
1	An on-line video education programme for couples with twins: a qualitative study	BMFMS	2010

[⌘]prize awarded

PRIZES AND AWARDS

No.	Award	Awarding Body	Year
2	Best presentation for 'Obstetric disasters for the non-Obstetrician'	BASICS South West	2014
1	Best poster for 'Comparison of the use of rectus sheath catheters with epidurals following midline laparotomy for gynaecological cancer as part of an Enhanced Recovery Program	Enhanced Recovery	2011

CONFERENCES ATTENDED

No.	Conference	Location	Year
33	British Gynaecological Cancer Society	London	2025
32	British Gynaecological Cancer Society	Liverpool	2024
31	British Society for Colposcopy and Cervical Pathology	Edinburgh	2024
30	British Gynaecological Cancer Society	Aberdeen	2023
29	East Midlands Gynae-Oncology Symposium	Virtual	2023
28	British Gynaecological Cancer Society	London	2022
27	British Society for Colposcopy and Cervical Pathology	Belfast	2022
26	European Society of Gynaecological Oncologists	Virtual	2021
25	British Gynaecological Cancer Society	Virtual Cheltenham	2021
24	East Midlands Gynae-Oncology Symposium	Virtual Derby	2021
23	International Gynecologic Cancer Society	Virtual	2020
22	Perinthalmanna Obstetric and Gynaecological Society (POGS)	Virtual Kerala	2020
21	British Gynaecological Cancer Society	Cambridge	2019
20	East Midlands Gynae-Oncology Symposium	Derby	2019
19	British Gynaecological Cancer Society	London	2018
18	East Midlands Gynae-Oncology Symposium	Derby	2018
17	British Society for Colposcopy and Cervical Pathology	Manchester	2018
16	European Society of Gynaecological Oncologists	Vienna	2017
15	Symposium on maximum effort cytoreductive surgery	Leicester	2017
14	International Gynecologic Cancer Society	Lisbon	2016
13	British Gynaecological Cancer Society	Birmingham	2016
12	Valedictory day of science – Professor David Leusley	Birmingham	2016
11	East Midlands Gynae-Oncology Symposium	Derby	2016
10	East Midlands Gynae-Oncology Symposium	Derby	2015
9	Gynaecological Oncology Fellows Meeting	Oxford	2014

8	British Gynaecological Cancer Society	London	2014
7	British Surgical Gynaecological Oncology Group	London	2014
6	East Midlands Gynae-Oncology Symposium	Derby	2014
5	European Society of Gynaecological Oncologists	Liverpool	2013
4	British Gynaecological Cancer Society	Belfast	2013
3	East Midlands Gynae-Oncology Symposium (organizer)	Derby	2013
2	South West O&G Society AGM	Torbay	2012
1	British Maternal and Fetal Medicine Society	Gateshead	2010

COURSES ATTENDED

RELATING TO MEDICOLEGAL PRACTICE:

No.	Qualification	Awarding Body	Year
2	Bond Solon: Report Writing for Expert Witnesses	Bond Solon	2026
1	Bond Solon: Courtroom Skills	Bond Solon	2026

RELATED TO GYNAECOLOGICAL ONCOLOGY:

No.	Course	Location	Year
12	HIPEC training	Derby	2026
11	PIPAC training	Cardiff	2025
10	Bowel re-anastomosis	Glasgow	2017
9	Clinical genetics	Southampton	2017
8	Gestational trophoblastic disease	Sheffield	2017
7	Care of the critically ill surgical patient	Edinburgh	2017
6	Masterclass in vulval disease	London	2016
5	Surgical anatomy for pelvic surgeons and gynaecological oncologists	Birmingham	2014
4	Advanced communication skills training	Nottingham	2013
3	Basic colposcopy	London	2013
2	Laparoscopic suturing	Truro	2012
1	Breaking bad news	Torbay	2008

RELATED TO EMERGENCY CARE:

No.	Course	Location	Year
5	Neonatal Life Support	Plymouth	2009
4	Advanced Trauma Life Support	Cheltenham	2007
3	Advanced Life Support	Torbay	2006
2	ALERT	Cheltenham	2006
1	Immediate Life Support	Bristol	2005

RELATED TO MANAGEMENT, PROFESSIONAL SKILLS AND RESEARCH:

No.	Course	Provider	Location	Year
6	Compassionate Leadership	UHDB/Kings Fund	Derby	2024-2025
5	Appraisal training	Miad Health Care	Online	2023
4	Educational supervisors Training	RCS	Derby	2018 - 2023
3	Good Clinical Practice	NIHR	NHS	2013 - 2025
2	Managing Professional Interactions	MPS	Cardiff	2012
1	Professional and Generic Skills	University of Plymouth	Plymouth	2011

TEACHING

ORAL PRESENTATIONS:

No.	Title	Location	Course	Year
14	Management of Stage 4(B) Ovarian Cancer: Surgical Approach	BGCS	BGCS Trainees Day	2026
13	Ovarian cytoreductive surgery	UHDB	Oncology Training Day	2025
12	Basic principles of hysterectomy	RCOG	Benign abdominal ATSM surgery course	2021-23
11	GynaeOncology for the MRCOG	BGCS Webinar	MRCOG revision course	2021
10	HRT and Gynaecological cancer	DELTA	HRT and menopause health	2020
9	Needles, Sutures and Knots	DELTA	Basic Surgical Skills	2019
8	Reducing the risk of ovarian cancer in BRCA carriers	Burton on Trent	GP education evening – Breast cancer team	2019
7	Gynaecological Oncology for the MRCOG	RCOG	MRCOG Pt2 revision	2018-22
6	Management of abnormal smears	RCOG	MRCOG Pt2 revision	2018
5	Pelvic and Para-aortic Lymphadenctomy	Nottingham City	Derby Cadaveric Dissection	2018
4	The non-gynaecological bits of Gynaecological Oncology	Derby	Registrar Teaching	2018
3	Gynaecological Oncology	Derby	MB ChB education	2018
2	Laparoscopic Entry	DELTA	Derby TLH Course	2014
1	Laparoscopic Entry	DELTA	Derby TLH Course	2014

FACULTY MEMBERSHIP:

No.	Course	Location	Year
6	RCOG Benign Abdominal Surgery	RCOG	2021→ 2024
5	Derby Gynaecological Oncology Symposium	Derby	2019→ Present
4	DELTA: Basic surgical skills	Derby	2019→ 2020
3	RCOG MRCOG Pt2 revision	RCOG	2018→ 2022

2	Derby Cadaveric Dissection	Nottingham City	2018→ Present
1	DELTA: TLH Course	Derby	2014→ 2018

AUDIT

PERSONAL AUDITS UNDERTAKEN:

No.	Title	Location	Year
19	Compliance with Ultraradical enhanced recovery pathway	Royal Derby	2020
18	ESGO quality standards (Cervix)	Royal Derby	2020→
17	ESGO quality standards (Ovary)	Royal Derby	2018→
16	Upstaging of High-Grade endometrial cancer	Royal Derby	2019
15	Cervical Cancer Survival and Outcome	Royal Derby	2019- 2020
14	Intraoperative Cytoreductive Surgical Outcomes	Royal Derby	2019
13	Advanced Ovarian cancer outcomes	Royal Derby	2018- 2019
12	Morbidity and mortality associated with ultraradical and standard surgery for advanced ovarian cancer	Birmingham City	2014- 2017
11	Use of CA125 in the follow-up of advanced ovarian cancers	Birmingham City	2016
10	Maternal and neonatal morbidity following personal obstetric interventions	Royal Derby/Royal Cornwall	2011- 2014
9	Ovarian cancer follow-up	Royal Derby	2013
8	Accuracy of discharge summaries¥	Royal Cornwall	2012
7	Medical management of ectopic pregnancy*	Royal Cornwall	2011
6	Uptake of flu vaccination in pregnancy	Royal Cornwall	2011
5	Pipelle efficacy and outcomes in PMB clinics	Royal Devon & Exeter	2010
4	Medical management of miscarriage	Royal Devon & Exeter	2009
3	Readmissions to McCallum (gynaecology) ward	Torbay	2008

2	IUCD insertion	Torbay	2007
1	Heavy menstrual bleeding	Torbay	2006

*Also as part of collaborative regional audit ¥ Supervision of junior colleague

INFORMATION TECHNOLOGY

No.	Qualification	Date
1	European Computer Driving License	2006

SERVICE DEVELOPMENT

PROJECTS UNDERTAKEN AS CONSULTANT:

No.	Title	Location	Year
17	HIPEC	Derby	2026
16	Prehabilitation pathway	Derby	2025
15	Salvage Chemotherapy pathway	Derby	2024
14	Update of Gynaecology Pathology Form	Derby	2021
13	ESGO accreditation for Ovarian Cancer Surgery. Achieved July 2020	Derby	2017-2020
12	RCOG accreditation for Subspeciality training.	Derby	2020
11	Streamlining 2WW referral pathways	Derby	2020
10	GP referral pathway: Derby, Burton, Chesterfield	Derbyshire CCG	2020→
9	Bowel obstruction pathway	Derby	2020
8	Liaison consultant for the Abnormal invasive placenta (AIP) service	Derby	2019→
7	Development of Red to Green hand over sheet	Derby	2019
6	Liaison for development of trust website; Development for Derby Gynaecological Cancer webpage, Family history of gynaecological cancer webpage and consultant profiles.	Derby	2019-2020
5	Construction of Gynae MDT database	Derby	2019
4	Enhanced recovery and preoperative pathways	Derby	2018-2020

for cytoreductive surgery

3	Online MDT Referral for MDT cases	Derby	2018
2	Preprinted consent form (TLH, Staging laparotomy, Cytoreductive surgery, TLH for Cancer, Radical Hysterectomy, Diagnostic laparoscopy)	Derby	2017
1	Patient information for Ultra radical surgery, Radical Hysterectomy, Bilateral Salpingoophorectomy	Derby	2017

MANAGEMENT (NHS)

No.	Role/event	Year
8	Lead Clinician for Cancer	2022-Present
7	Compassionate and Inclusive Senior Leadership Programme, delivered in partnership with Kings Fund and Aqua	2024-2025
6	Edward Jenner Programme (NHS Leadership)	2020-2021
5	Organizer: East midlands Gynaecological Oncology symposium: Advanced Ovarian cancer	2019, 2022
4	Lead for Peer review 2018	2019
3	Lead for Gynaecological cancer: Incorporating Guideline development, Pathway refinement and minimizing Breaches, hosting 4-monthly operational meetings, Chairing the Gynaecological Cancer MDT.	2018→
2	Gynaecological Lead for the 100,000 genomes project	2017→2020
1	Lead for Family History Clinic.	2017→

Compassionate and Inclusive Senior Leadership Programme, delivered in partnership with Kings Fund and Aqua encompassed:

- Module 1 = launch session
- Module 2 = Who matters & what matters? Exploring programme purpose, content and expectations, and creating the learning system for the cohort
- Module 3 = Fundamentals of Compassionate and Inclusive leadership
- Module 4 = Developing a learning & improvement culture
- Module 5 = Creating clarity of purpose, strategic alignment and co-ordinating resources for better outcomes
- Module 6 = Making the leadership culture normal – developing an all-lead all follow leadership culture
- Module 7 = Consolidation & planning for ongoing personal and shared

development after the formal programme finishes

- 3 Action Learning Sets (ALS),
- 2 improvement coaching sessions
- Practical learning project for each participant
- On-line resources
- Work between modules to embed learning

LOCAL GUIDELINES

Date	Role/event	Year
14	Guideline: Endometrial Cancer	2026
13	Guideline: Operation policy introduction & Appendix	2024
12	Guideline: Vulval Cancer	2022
11	Guideline: Ovarian Cancer	2022
10	Guideline: Screening for Gynaecological cancer and risk reducing surgery in women at high risk of Ovarian / Fallopian tube or endometrial cancer.	2022
9	Management of 2WW Gynaecological Oncology referrals during the Coid-19 Pandemic	2020
8	Surgical Management of Gynaecological Oncology Patients during the Coid-19 Pandemic	2020
7	Operational Policy: Gynecological Cancer	2019
6	Guideline: Vaginal Cancer	2019
5	Guideline: Endometrial Cancer	2019
4	Guideline: Vulval Cancer	2019
3	Guideline: Cervical Cancer	2019
2	Guideline: Ovarian Cancer	2019
1	Guideline: Screening for Gynaecological cancer and risk reducing surgery in women at high risk of Ovarian / Fallopian tube or endometrial cancer.	2018